



Dyslipidemia initiates keratinocytes proliferation through upregulation of lncRNA NEAT in psoriasis patients

Abeer Mostafa¹ · Dina Sabry^{1,2} · Nesreen Aboraia³ · Ahmed Fawzy⁴ · Amany A. Abou-Elalla⁵

Received: 26 July 2022 / Accepted: 15 May 2023 / Published online: 2 August 2023
© The Author(s) 2023

Abstract


Background Psoriasis is a chronic inflammatory immune-mediated and hyper proliferative skin disorder that has underlying genetic factors. Psoriasis can result from interaction of cytokines between keratinocytes and T-lymphocytes. NEAT is a lncRNA involved in immune modulation and has been previously studied in cancers. This study aims to clarify the unprecedented role of NEAT in psoriasis pathogenesis.

Methods The study was conducted on 50 healthy control subjects and 50 psoriasis patients. Blood samples from all participants were collected for analysis of their lipid profile. qRT-PCR was done for lncRNA NEAT, TNF- α , VEGF genes expression. The levels of ROS and caspase-3 were estimated by ELISA. ROC analysis was done to detect the diagnostic value of lncRNA NEAT gene expression.

Results Dyslipidemia is more prevalent among psoriasis patients. A significant up regulation in lncRNA NEAT, TNF- α , VEGF genes expression (p value \leq 0.001) in psoriasis patients in addition to significant increase in ROS and caspase-3 levels (p value \leq 0.001) in compare to controls. Additionally, a positive significant correlation between TNF- α , ROS, NEAT, caspase-3 and dyslipidemia. NEAT had an area under the curve (AUC) of 0.931 (95% CI 0.844–0.978, p < 0.001).

Conclusion Dyslipidemia is an initiating signal in psoriasis pathogenesis that creates a state of chronic inflammation and oxidative stress. This state induces keratinocytes proliferation and release of NEAT with subsequent caspase-3 activation to counteract the proliferating cells. NEAT could be considered as a good diagnostic biomarker for psoriasis.

Graphical abstract



Keywords Psoriasis · NEAT · TNF- α · VEGF · ROS · Caspase-3

Introduction

Psoriasis is a chronic inflammatory disease affects mainly joint and skin. Psoriasis has bad emotional and psychosocial impact on patients [1]. Psoriasis is characterized by

excessive proliferation of keratinocytes and infiltration of the immune cells in the epidermis and dermis [2].

In the past several years; many researches were developed on long non-coding RNAs (lncRNAs) due to its vital role in biological process regulation [3]. lncRNAs have a crucial role in epigenetic regulation, by formation of networks composed of chromatin regulators and ribonucleoproteins [4].

Extended author information available on the last page of the article

Several previous studies revealed that lncRNAs are expressed in different stages of immune development, activation. LncRNAs had been shown to be involved in many diseases, such as autoimmune disorders including rheumatoid arthritis, systemic lupus erythematosus, and psoriasis. Recently it has been demonstrated that lncRNA NEAT acts as a novel regulatory factor in the immune system [5].

Paraspeckles are a huge network of protein-protein interaction that seemed to be hold together by the lncRNA NEAT with other cellular regulatory proteins [6].

Tumor necrosis factor- α (TNF- α) is a multifunctional cytokine. TNF plays an crucial role in immunological and inflammatory responses in human skin. It had been reported that TNF plays a vital role in psoriasis development. TNF- α could induce reactive oxygen species (ROS) generation in human keratinocytes, I κ B degradation with subsequent nuclear translocation of nuclear factor kappa B (NF- κ B), p65, and inflammatory cytokines production [7].

Oxidative stress is only partly responsible for psoriasis, however in general it can be stated that excessive oxidative is present in patients suffering from psoriasis. ROS are generated from both external pro-oxidant stimuli and endogenous neutrophils, these results in increased ability of chemotaxis, adhesion, and fibroblasts activation. This is approved high MDA plasma levels and decreased the antioxidant defense enzymes levels in psoriasis patients [8].

Active caspase enzyme can mediate pro-inflammatory cytokines proteolytic maturation and induce apoptosis. Caspases activation is crucial for the defense against damaged cells and pathogens, their dysregulation could contribute to cancer, autoimmune, and neurodegenerative diseases [9].

NEAT1 stabilizes the mature caspases to promote cytokines production and initiates apoptosis. Inflammatory signals induce NEAT1 activation through its dissociation and translocation from the paraspeckles to the cytoplasm to affect the inflammatory and immune cells [10].

Subjects and methods

Study subjects

One hundred participants matched sex and age (ranging from 35 to 55) years were included in the study, according to ethical approval N-94-2023 obtained from Research Ethics Committee, Faculty of Medicine, Cairo University.

An informed consent was obtained from all participants. The psoriasis patients were enrolled from the dermatology outpatient clinic, Faculty of Medicine, Cairo University. Sample size was calculated using the (G power software). Based on (Young et al.) [7] we found that 50 participants in each group was appropriate sample size with total sample size 100 participants (2 groups) The power is 80% and α error probability = 0.05, effect size $f = 0.57$.

The participants were divided into two: Group 1: 50 healthy controls. Group 2: 50 psoriasis patients. Five ml whole blood were withdrawn from all participants. Three ml were proceeded for RNA extraction followed by real time PCR for quantitative assessment of lncRNA NEAT, TNF- α and VEGF genes expression. The last two ml were centrifuged at 3000 \times g for 15 min to separate clear plasma and stored at -80°C for further assessment of ROS and Caspase-3 levels by ELISA. Additionally, Lipid profile was assessed in plasma using spectrophotometer. TAG (mg/dL), cholesterol (mg/dL), and HDL (mg/Dl) were measured.

RNA extraction

From whole blood samples after about 2 weeks of samples storage in -80° ; total RNA was extracted from the two studied groups using Direct-zolTM RNA MiniPrep Catalog. No.: R2050. ZYMO RESEARCH according to the instructions of manufacturer. RNA purity and quantitation assessment were carried out using spectrophotometer the Nano Drop[®] (ND)-1000 (Nano Drop Technologies, Inc. Wilmington, USA). For Quantitative Real-Time Polymerase Chain Reaction (qPCR);

One-Step Kit SensiFASTTM SYBR[®] Hi-ROX, Catalog No. PI-50217 V was used for cDNA synthesis and qPCR using a single tube in the 48-well plate Step One instrument (Applied Biosystem, USA) on a Rotor Gene Real-Time PCR System (Qiagen). Genes expressions were normalized to GAPDH by the $\Delta\Delta\text{Ct}$ method. The thermal profile of the PCR run was adjusted as follows: 45 $^{\circ}\text{C}$ for 15 min in one cycle (for cDNA synthesis), 10 min at 95 $^{\circ}\text{C}$ for reverse transcriptase enzyme inactivation, followed by 40 cycles of PCR amplification. Each cycle in the form of 10 s at 95 $^{\circ}\text{C}$, 30 s at 60 $^{\circ}\text{C}$, and 30 s at 72 $^{\circ}\text{C}$. the sequence of studied genes primers is listed in Table 1.

Table 1 primers sequence of all the studied genes

| | Forward | Reverse |
|-------|------------------------------|------------------------------|
| VEGF | 5'-GAGATGAGCT TCCTACAGCAC-3' | 5'-TCACCGCCTCGGCTTGTCACAT-3' |
| NEAT | 5'-GTGGCTGTTGGAGTCGGTAT-3 | 5'-TAACAAACCACGGTCCATGA-3' |
| TNF | 5'- CTCTTCTGCCTGCTGCACTTTG-3 | 5'- ATGGGCTACAGGCTTGCTACTC-3 |
| GAPDH | 5'- GTCTCCTTGACTTCAACAGCG-3 | 5'- ACCACCCTGTTGCTGTAGCCAA-3 |

ELISA

The plasma levels of ROS ($\mu\text{g/ml}$) from the two studied groups were estimated using human ROS ELISA Kit. Catalog No: MBS251578. BioSource according to kits instructions.

The plasma levels of active caspase-3($\mu\text{g/ml}$) from the two studied groups were estimated using human caspase 3 ELISA Kit, Catalog No: KHO1091. Labome according to kit instructions.

Biochemical assessments

Measurements of lipid profile were carried out by colorimetric technique using reagent kits (total cholesterol Catalog No: CH 12 20, HDL Catalog No: CH 12 30, and triglyceride Catalog No: CH 20 30) Biodiagnostic Egypt.

Statistical method

SPSS program version 22 was used for data analysis. Normality tests Kolmogorov-Smirnov and Shapiro-Wilk were used for exploration data normality and distribution. Data are presented as mean and standard deviation. Independent sample t test was used for comparison between the two studied groups regarding the numerical variables. χ^2 test was used for qualitative data comparisons. Pearson correlation was used for the correlation between quantitative variable. Receiver operating characteristic (ROC) curve analysis was done to detect best diagnostic chosen cutoff value of LncRNA NEAT. $P \leq 0.05$ is considered to be significant.

Results

Demographic and laboratory characteristics of psoriasis patients

The demographic and laboratory data analysis of the two studied groups revealed that there was no significant difference regarding the age and sex between the two studied groups (p value > 0.05). A significant increase in plasma TG and cholesterol and decrease in HDL levels in psoriasis patients when compared to the control subjects (p value = 0.008, < 0.001 , < 0.001) respectively. Table 2.

qRT PCR for lncRNA NEAT, VEGF and TNF- α genes expression

Regarding PCR results; a significant increase in lncRNA NEAT, VEGF and TNF- α genes expression in

Table 2 Demographic and biochemical laboratory data among the studied groups

| Variable | Control Group (I) n = 50 | Psoriasis Group (II) n = 50 | <i>p</i> value |
|--------------------|-----------------------------|--------------------------------|----------------|
| Sex | | | |
| Females: n (%) | 42 (42%) | 46 (46%) | 0.87 |
| Males: n (%) | 58 (58%) | 54 (54%) | |
| Age (years) | 43.1 \pm 10.9 | 45.7 \pm 15.6 | 0.36 |
| TG (mg/dl) | 100.6 \pm 26.2 | 127.3 \pm 64.5* | 0.008 |
| Cholesterol(mg/dl) | 116.7 \pm 34.2 | 180.2 \pm 45.7* | < 0.001 |
| HDL | 51.2 \pm 8.5 | 35.8 \pm 10.4* | < 0.001 |

Data were expressed as Mean \pm SD, p value < 0.05 was significant

*Denotes significant difference versus control subjects

TG tri glyceride, HDL high density lipoprotein

psoriasis patients as compared to healthy control subjects (p value < 0.001). Figure 1a–c respectively.

ELISA for caspase-3 and ROS plasma levels

Regarding ELISA results; a significant increase in caspase-3 and ROS plasma levels in psoriasis patients while compared to healthy control subjects (p value < 0.001) Fig. 1d, e respectively.

Correlation analysis between NEAT and other studied parameters with lipidemic state of psoriasis patients


Plasma cholesterol was significantly positively correlated with all studied parameters while HDL was inversely correlated with them (p value < 0.001). A significant positive correlation between ROS, TNF- α levels and NEAT and caspase-3 (p value < 0.001) as showed in Table 3.

Table 3 Correlation between all studied parameters

| | | TNF- α | NEAT | ROS | Caspase 3 |
|---------------|---------|---------------|-----------|-----------|-----------|
| TG | r | 0.200* | 0.028 | 0.096 | 0.128 |
| | P value | 0.046 | 0.780 | 0.341 | 0.204 |
| Cholesterol | r | 0.345** | 0.301** | 0.531** | 0.471** |
| | P value | < 0.001 | 0.002 | < 0.001 | < 0.001 |
| HDL | r | -0.463** | -0.519** | -0.442** | -0.340** |
| | P value | < 0.001 | < 0.001 | < 0.001 | 0.001 |
| TNF- α | r | 1 | 0.590** | 0.463** | 0.376** |
| | P value | | < 0.001 | < 0.001 | < 0.001 |
| NEAT | r | 0.590** | 1 | 0.473** | 0.435** |
| | P value | < 0.001 | | < 0.001 | < 0.001 |

* denotes that p value < 0.05

** denotes that p value < 0.01



Data were expressed as mean \pm SD. *p* value less than 0.05 is considered significant

(*): denotes significant difference versus control groups

Fig. 1 A statistically significant increase in all studied parameters (a-NEAT, b-VEGF, c-TNF- α , d-caspase 3 and e-ROS) in psoriasis patients as compared to controls. Data were expressed as mean \pm SD.


p value less than 0.05 is considered significant *denotes significant difference versus control groups (kindly insert the legend below the figure)

Table 4 ROC analysis of NEAT

| AUC | P value | Cut off | Sensitivity | Specificity | 95% Confidence interval | |
|-------|---------|---------|-------------|-------------|-------------------------|-------------|
| | | | | | Lower bound | Upper bound |
| 0.931 | <0.001 | 1.28 | 82% | 90% | 0.884 | 0.978 |

AUC Area under the curve

Fig. 2 ROC curve to predict the diagnostic value of NEAT in psoriasis patients from controls. ROC curve showed that the expression of NEAT could be used as a predictor of psoriasis. NEAT had an area under the curve (AUC) of 0.931 (95% CI 0.884–0.978, $p < 0.001$)



ROC analysis to determine the diagnostic performance of NEAT

ROC analysis for lncRNA NEAT revealed that it could be considered as a good diagnostic marker for psoriasis. The best chosen cutoff level was 1.28, at which the AUC was 0.931, the specificity was 90% and the sensitivity was 82%. Figure 2; Table 4.

Discussion

Psoriasis is an inflammatory, systemic disease characterized by an increase in the immune-related cells release of pro-inflammatory cytokines. Psoriasis not only dermatological disorder but also associated with many comorbidities, like psoriatic arthritis, cardiovascular and psychiatric complications [11].

In this study we found a state of dyslipidemia in psoriatic patients in the form of increased TG, cholesterol levels and decrease in HDL level. this is agreed with previous studies revealed elevated TG, cholesterol, LDL, and decreased HDL in psoriasis patients [12, 13] in addition many studies reported that dyslipidemia in psoriasis patients is associated with increase in the risk of cardiovascular disease [14, 15].

Interestingly, we found significant positive correlation between the dyslipidemia and the levels of inflammatory cytokine TNF and ROS; this may suggest that the dyslipidemia

acts as initiating signal in chronic inflammatory process in psoriasis. These finding coincides with previous studies reported that the treatment of associated hyperlipidemia induces clinical improvement in psoriasis manifestation which could be attributed to anti-inflammatory and immunomodulatory effects [16]. Oxidative stress has been believed to be a key regulator in the pathogenesis of psoriasis. ROS produced by fibroblasts, keratinocytes, and endothelial cells produce chemotaxis on neutrophils and other inflammatory cells in addition to their accumulation in psoriatic lesions with subsequent excessive superoxide (O_2^-) production during phagocytosis [17].

We also found significant increase in TNF gene expression and ROS levels in psoriasis patients compared to the control, these are concordant with the previous studies reported that psoriasis is characterized by an abnormal differentiation and proliferation of keratinocytes, caused by a dysregulated auto-immune T cell response to several inflammatory cytokines [18]. TNF α , is secreted by both T cells and antigen-presenting cells within psoriasis skin lesion, more over TNF antagonists become a new modality in treatment of moderate-to-severe psoriasis [19]. TNF- α produces induction of adhesion molecules on vascular endothelial cells causing stimulation of keratinocytes production of other pro-inflammatory mediators [20]. Another study revealed significantly increased serum ROS like nitric oxide, malondialdehyde with decrease in the antioxidant activity of superoxide, catalase psoriasis patients compared to the control [21].

VEGF is a key growth factor that cause regulation of the neovascularization, during embryogenesis, and pathological processes [22]. We found significant up regulation of VEGF gene expression in psoriasis patients compared to controls, this is agreed with previous studies on psoriatic patients reported that serum levels of VEGF were significantly higher in psoriasis patients than control subjects and a highly significant correlation between VEGF and PASI score was found, suggesting that VEGF can be a good indicator for severity of the disease [23].

On an attempt to identify the epigenetic regulation of psoriasis pathogenesis, we investigated the expression of lncRNA NEAT and found significant up regulation of its expression in psoriasis patients compared to controls, NEAT is one of lncRNAs involved in inflammation and modulation of the immune system. NEAT are thought to maintain the integrity of the paraspeckles structure; up on inflammatory stimulation, NEAT is translocated to the cytoplasm, activating various caspases [24]. Moreover, previous studies revealed that NEAT has a role in cancers by regulating apoptosis and cell cycle progression in breast cancer cells [25].

Another study reported that NEAT has a critical role in regulation of cell growth, proliferation, apoptosis, invasion and metastasis. In addition, expression level of NEAT in tumor tissues associated with survival of cancer patients indicating that NEAT could be a therapeutic target in cancer treatment [26].

ROC curve was done to evaluate the diagnostic value of lncRNA NEAT as a predictor for discrimination between psoriasis patients and controls; At cut-off points of 1.28 at which the AUC was 0.931, the sensitivity was 82% and the specificity was 90%, NEAT could be considered a good diagnostic biomarker for psoriasis.

Apoptosis is a programmed cell death. dysregulated apoptosis can lead neoplastic or autoimmune diseases such as psoriasis. Caspase-3 is a marker of apoptosis [27]. we found significant increase in caspase 3 level in psoriasis patients compared to controls, this is in accordance with a study revealed that over expression of caspase-3 in the psoriatic lesion has a potential role in psoriasis pathogenesis and the positive correlation between the caspase-3 expression and poor prognostic of psoriasis lesion [28]. However contrary reports revealed that physiological apoptosis is crucial in normal epidermis development; and the induction of apoptosis is involved in the regression of psoriatic hyperplasia after PUVA therapy; moreover, decrease of physiological apoptosis in the psoriatic lesion could lead to psoriatic hyperplasia [29], this is also augmented by another report stated that apoptosis regulates keratinocyte proliferation. Dysfunctional apoptosis has a key role in hyper proliferation with incomplete differentiation of epidermal keratinocytes; further more psoriatic keratinocytes have the ability to resist apoptosis, which is a key regulator in development of psoriasis [30].

Thus, we can conclude that dyslipidemia is more prevalent in psoriasis patients. Dyslipidemia seems to act as initiator signals in development of psoriasis through secretion of inflammatory cytokines and increase the oxidative stress. Cytokines and ROS stimulate two pathways; the first one is modulation of immune cells and stimulation of keratinocyte proliferation and development of psoriatic lesion; the second pathway is the release of NEAT from paraspeckles to counter act the inflammation and activate apoptosis through induction of caspase-3. Thus, the increased expression of NEAT and caspase-3 levels seemed to be a protective and counteracting epigenetic regulator in psoriasis.

Author contributions AM: Conceptualization, Methodology, Software, Writing—Original draft preparation, Reviewing and Editing; DS: Methodology; NA: Data curation, Visualization, Writing—Reviewing and Editing; AF: Data curation, Visualization, Writing—Reviewing and Editing. AAAE: Data curation, Visualization, Writing—Reviewing and Editing. All authors read and approved the final manuscript.

Funding Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Data availability The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Competing interests The authors have no relevant financial or non-financial interests to disclose.

Ethical approval This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by Research Ethics Committee, Faculty of Medicine, Cairo University N-94-2023.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Kim WB, Jerome D, Yeung J (2017) Diagnosis and management of psoriasis. *Can Fam Phys* 63(4):278–285
2. Greb JE, Goldminz AM, James T et al (2016) Psoriasis. *Nat Rev Dis Prim* 2:16082

3. Esteller M (2011) Non-coding RNAs in human disease. *Nat Rev Genet* 12:861–874
4. Kretz M, Webster DE, Flockhart RJ, Lee CS, Zehnder A, Lopez-Pajares V et al (2012) Suppression of progenitor differentiation requires the long non-coding RNA ANCR. *Genes Dev* 26:338–343
5. Zhang F, Wu L, Qian LBOQ (2016) Identification of the long noncoding RNA NEAT1 as a novel inflammatory regulator acting through MAPK pathway in human lupus. *J Autoimmun* 75:96–104
6. Sven H, Geraldine K, Taro M, Agata S, Simon K, Newcombe AB, Hosoki K, Goshima N, Kawaguchi T, Hatters D, Trinkle-Mulcahy L, Hirose T, Bond CS, Fox AH et al (2015) Prion-like domains in RNA binding proteins are essential for building subnuclear paraspeckles. *J Cell Biol* 210(4):529–539
7. Young CN, Koepke JI, Terlecky LJ, Borkin MS, Boyd Savoy L, Terlecky SR (2009) Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. *J Invest Dermatol* 129(7):1838. <https://doi.org/10.1038/jid.2008.122>
8. Hristakieva E, Gadjeva V (2003) Seasonal variations in the activity of antioxidant enzymes and lipid peroxidation in psoriatic and vitiligo patients. *Trakia J Sci* 1(1):27–31
9. Van O (2014) Activation of the NLRP1b inflammasome independently of ASC-mediated caspase-1 autoproteolysis and speck formation. *Nat Commun* 5:3209
10. Zhang P, Cao L, Zhou R, Yang X, Wu M (2019) The lncRNA NEAT1 promotes activation of inflammasomes in macrophages. *Nat Commun* 10(1):1495. <https://doi.org/10.1038/s41467-019-09482-6>
11. Kim N, Thrash B, Menter A (2010) Comorbidities in psoriasis patients. *Semin Cutan Med Surg* 29:10–15
12. Nakhwa YC, Rashmi RA, Basavaraj KH (2014) Dyslipidemia in psoriasis: a case controlled study. *Int Sch Res Not* 2014, 729157
13. Mi -C, Li J, Li Y, Zh X (2019) Obesity and dyslipidemia in patients with psoriasis. A case-control study. *Medicine* 98(31), e16323
14. Arora T, Krishna A, Rathore BS, Srivastava D (2016) Association of dyslipidemia with psoriasis: a case-control study. *J Obes Metab Res* 3:37–40
15. Priya H, Maria K (2013) Dyslipidemia in psoriasis: as a risk for cardiovascular disease. *IJRMS*
16. Ghazizadeh R, Tosa M, Ghazizadeh M (2011) Clinical improvement in psoriasis with treatment of associated hyperlipidemia. *Am J Med Sci* 341(5):394–398. <https://doi.org/10.1097/MAJ.0b013e3181ff8eeb>
17. Wagener FA, Carels CE, Lundvig DM (2013) Targeting the redox balance in inflammatory skin conditions. *Int J Mol Sci* 14:9126–9167
18. Rosalba B, Caterina F, Maria T (2018) The psoriasis pathogenesis and the metabolic risk. *Open Dermatol J* 12:1
19. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, Fuentes-Duculan J et al (2007) Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. *J Exp Med* 204:3183–3194. <https://doi.org/10.1084/jem.20071094>
20. Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA et al (2005) TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. *J Immunol* 175:2721–2729
21. Kadam DP, Suryakar AN, Ankush RD, Kadam CY, Deshpande KH (2010) Role of oxidative stress in various stages of psoriasis. *Indian J Clin Biochem* 25(4):388–392. <https://doi.org/10.1007/s12291-010-0043-9>
22. Marina ME, Roman II, Constantin AM, Miha CM, Tătaru AD (2015) VEGF involvement in psoriasis. *Clujul Med* 88(3):247–252. <https://doi.org/10.15386/cjmed-494>
23. Nofal A, Al-Makhzangy I, Attwa E, Nassar A, Abdalmoati A (2009) Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control. *J Eur Acad Dermatol Venereol* 23(7):803–806. <https://doi.org/10.1111/j.1468-3083.2009.03181.x>
24. Sasaki YTF, Ideue T, Sano M, Mituyama T, Hirose T (2009) MEN epsilon/beta noncoding RNAs are essential for structural integrity of nuclear paraspeckles. *Proc Natl Acad Sci USA* 106:2525–2530
25. Vivian Y, Shin J, Isabella W, Man-Ting S, Chi-Wang H, Hongchuan J et al (2019) Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness. *Cell Death Dis* 10:270
26. Soudeh G, Farda M (2019) Nuclear enriched abundant transcript 1 (NEAT1): a long non-coding RNA with diverse functions in tumorigenesis. *Biomed Pharmacother* 111:51–59
27. Kaštelan M, Prpić-Massari L, Brajac I (2009) Apoptosis in psoriasis. *Acta Dermatovenereol Croatica* 17(3):182–186
28. Bebars SM, Al-Sharakly MA, Afify DR (2017) Immunohistochemical expression of Caspase-3 in Psoriasis. *J Clin Diagn Res* 11(7):EC01–EC05. <https://doi.org/10.7860/JCDR/2017/25609.10145>
29. Laporte M, Galand P, Fokan D, de Graef C, Heenen M (2000) Apoptosis in established and healing psoriasis. *Dermatology* 200(4):314–316
30. Marija K, Larisa P (2009) Ines Brajac. Apoptosis in psoriasis. *Acta Dermatovenereol Croat* 17(3):182–186

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Abeer Mostafa¹ · Dina Sabry^{1,2} · Nesreen Aboraia³ · Ahmed Fawzy⁴ · Amany A. Abou-Elalla⁵

✉ Abeer Mostafa
dr_abeer.mostafa@cu.edu.eg; abeer.mostafa@kasralainy.edu.eg;
dr_abeer.mostafa@yahoo.com

Dina Sabry
dinasabry@kasralainy.edu.eg

Nesreen Aboraia
nesreen_aboraia@yahoo.com

Ahmed Fawzy
Dr.ahmadnofal81@gmail.com

Amany A. Abou-Elalla
amany.abouella@must.edu.eg

¹ Medical Biochemistry and Molecular Biology department, Faculty of Medicine, Cairo University, Cairo, Egypt

² Medical Biochemistry and Molecular Biology department, Faculty of Medicine, Badr University in Cairo, Badr City, Egypt

- ³ Dermatology department, Faculty of Medicine, Fayoum University, Fayoum, Egypt
- ⁴ Physiology department, Faculty of Medicine, Cairo University, Cairo, Egypt

- ⁵ Medical Laboratory Technology department, Faculty of Applied Health Science Technology, Misr University for Science and Technology, 6th of October City, Egypt